Código QR (código de barras bidimensional)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy

Crizotinib is an oral selective small-molecular tyrosine kinase inhibitor (TKI) that suppress the activity of anaplastic lymphoma kinase (ALK) and ROS1 kinases, as well as mesenchymal-epithelial transition. The cumulative clinical trials in patients with advanced ALK- or ROS1-rearrangement NSCLC ind...

ver descrição completa

Na minha lista:
Principais autores: Woo Kyung Ryu, Hyungkeun Cha, Mi Hwa Park, Jung Soo Kim, Jeong-Seok Choi, Lucia Kim, Kyung-Hee Lee, Hae-Seong Nam
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2022-10-01
coleção:Frontiers in Oncology
Assuntos:
interstitial lung disease (ILD)
ALK (anaplastic lymphoma kinase)
ROS1
tyrosine kinase inhibitor (TKI)
crizotinib
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2022.900966/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados